HPV Testing And Pap Test Industry Overview
The global HPV testing and Pap test market size was valued at USD 1.7 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 16.4% from 2021 to 2028. Technological advancements, increasing number of cervical cancer screening programs, and high incidence of cervical cancer are some major factors driving the market for HPV testing and Pap test. However, the outbreak of Covid-19 and the implementation of restrictions to stay-at-home across the globe have rigorously reduced routine cancer screenings. The decline in screenings was steep and swift; as of April 25, 2020, the decline recorded for breast and cervical cancer screening was 94%. During the lockdown, screening of cervical cancer decreased to 80% relative to the baseline, among the 1.5 million population of women is the Kaiser Permanente Southern California (KPSC) network. Segmenting the screening as per age, for women aged between 21 and 29, screening rates of cervical cytology per 100 individual months declined 78%. For women aged between 30 and 65, HPV test screening rates declined 82% per 100 person-months. Gather more insights about the market drivers, restrains and growth of the Global HPV Testing And Pap Test Market Cervical cancer is among the most common cancers among women above the age of 40. According to estimates from the WHO, cervical cancer is the fourth most frequent cancer, with approximately 570,000 cases and over 311,000 deaths in 2018. It is estimated that approximately 99% of cervical cancer cases are typically linked with HPV infections. Cervical cancer is mostly diagnosed among women aged between 35 and 44 with the average rate of diagnosis being at 50 years. According to data from the U.S. Department of Health and Human Services, the rate of new cervical cancer cases was estimated to be around 7.4 per 100,000 women, with the death rate being 2.2 per 100,000 women each year. Growing demand for technologically advanced diagnostic procedures for screening cervical and vaginal cancers is one of the crucial factors expected to drive the market for HPV testing and Pap test over the forecast period. Various technological advancements, such as the development of HPV-type 16 E7-specific human immunologic assays used in non-HLA2 types, cobas system approvals, and usage of various molecular markers in screening procedures, are expected to drive the market for HPV testing and Pap test. In 2019, researchers at Massachusetts General Hospital's Center for Systems Biology and Harvard Medical School, Boston presented a novel screening handheld device that uses Artificial Intelligence (AI) for HPV detection. The novel device detects the presence of HPV strains 16 and 18 in a turnaround time of 2 hours. Similarly, researchers at Pathogen Discovery Laboratory have developed a diagnostic device that detects the presence of precancerous markers in HPV diagnosis. Furthermore, the rising number of awareness programs by various organizations, such as the National Cervical Cancer Coalition, WHO, CDC, and the U.S. Preventive Services Task Force (USPSTF), for cervical cancer screening is one of the major factors expected to drive the market for HPV testing and Pap test during the forecast period. In March 2019, the U.K. government rolled out its first national cervical screening campaign called Cervical Screening Saves Lives. The campaign run by Public Health England (PHE) was initiated owing to a reduced number of screenings by women in the U.K. The campaign was used to facilitate increased awareness about the disease and initiate screening of the disease. Browse through Grand View Research's Clinical Diagnostics Industry Research Reports. • Malaria Diagnostics Market: The global malaria diagnostics market size was valued at USD 728.8 million in 2021 and is anticipated to witness a CAGR of 5.4% during the forecast period. The rising demand for malaria diagnostics and the introduction of novel diagnostic techniques are the key factors driving the market. • Neglected Tropical Diseases Diagnosis Market: The global neglected tropical diseases (NTD) diagnosis market size was valued at USD 6.09 billion in 2021 and is expected to expand at a CAGR of 4.4% during the forecast period. Growing awareness of NTDs and an increasing number of initiatives undertaken by the government are anticipated to fuel the market growth. HPV Testing And Pap Test Market Segmentation Grand View Research has segmented the global HPV testing and Pap test market on the basis of test type, application, product, technology, end-use, and region: HPV Testing & Pap Test Type Outlook (Revenue, USD Million, 2016 - 2028) • HPV Testing • Pap Test HPV Testing & Pap Test Application Outlook (Revenue, USD Million, 2016 - 2028) • Cervical Cancer Screening • Vaginal Cancer Screening HPV Testing & Pap Test Product Outlook (Revenue, USD Million, 2016 - 2028) • Instruments • Consumables • Services HPV Testing & Pap Test Technology Outlook (Revenue, USD Million, 2016 - 2028) • PCR • Immunodiagnostics • Other Technologies HPV Testing & Pap Test End-use Outlook (Revenue, USD Million, 2016 - 2028) • Hospitals & Clinics • Laboratories • Others HPV Testing & Pap Test Regional Outlook (Revenue, USD Million, 2016 - 2028) • North America • Europe • Asia Pacific • Latin America • MEA Key Companies profiled: Some prominent players in the Global HPV Testing And Pap Test Market include • Abbott Laboratories • Qiagen N.V. • Becton, Dickinson and Company • Quest Diagnostics, Inc. • Hologic, Inc. • F. Hoffmann-La Roche • Femasys, Inc. • Arbor Vita Corporation • NURX, Inc. • Seegene, Inc. • Thermo Fisher Scientific, Inc. • bioMérieux SA Order a free sample PDF of the HPV Testing And Pap Test Market Intelligence Study, published by Grand View Research.
0 Comments
Digital Patient Monitoring Devices Market Business Standards and Competition Landscape to 20289/16/2022 Digital Patient Monitoring Devices Industry Overview
The global digital patient monitoring devices market size was estimated at USD 62.6 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 23.5% from 2021 to 2028. Rising demand for continuous monitoring devices and increasing prevalence of chronic diseases such as diabetes, hypertension, cardiovascular diseases, and others are factors propelling the growth of the market. In recent years, the adoption of sensor-based wearable devices such as continuous glucose monitors, ECG, and others is increasing among patients as well as healthcare providers. These devices can track the patient’s vital signs on a real-time basis which can then be transmitted to their doctors electronically and can also be integrated with the EHR. This allows the providers to continuously monitor the patient eliminating the need for frequent hospital visits. The rising demand for wearable devices has encouraged key players to carry intensive research and launch innovative products in the market for digital patient monitoring devices. For example, in March 2020, Somatix, Inc. announced the launch of an AI-powered continuous remote patient monitoring system. The introduction of similar innovative products is anticipated to augment the digital patient monitoring device market growth. Gather more insights about the market drivers, restrains and growth of the Global Digital Patient Monitoring Devices Market Incorporating digital patient monitoring systems can help in significant cost savings, thereby reducing the overall healthcare cost. Many countries across the globe are dealing with the economic burden of chronic diseases. According to the Centers for Disease Control and Prevention, heart disease and stroke costs around USD 214 billion to the U.S. healthcare system every year. With the use of digital patient monitoring systems, people at risk can be monitored remotely, thus preventing hospitalization and reducing healthcare costs. This is likely to favor the growth of the market for digital patient monitoring devices in the coming years. The COVID-19 pandemic brought a digital revolution in the healthcare industry by increasing the demand for wearable devices, mHealth apps, and telehealth by multiple folds. To control the spread of infection and patient volumes, hospitals were forced to shut down their OPDs and shift to digital health. According to a survey conducted by VivaLNK, a connected healthcare solution provider, 55% of the respondents were using or planning to use Remote Patient Monitoring (RPM) for COVID-19 patients. The government of many countries has started embracing digital health tools after realizing their potential. For instance, in April 2020, the Federal Communications Commission started a COVID-19 relief program which provided USD 200 million to equip hospitals with telehealth technology. This has opened new opportunities for the market players and start-up companies to develop innovative solutions. For example, in May 2020, VitalConnect, Inc. received Emergency Use Authorization Browse through Grand View Research's Medical Devices Industry Research Reports. • Phototherapy Equipment Market: The global phototherapy equipment market size was valued at USD 368.8 million in 2021 and is anticipated to witness a compound annual growth rate (CAGR) of 3.95% during the forecast period. The rising prevalence of skin diseases is the key factor driving the market growth. • Optical Imaging Systems Market: The global optical imaging systems market size was valued at USD 1.80 billion in 2021 and is expected to expand at a CAGR of 11.2% from 2022 to 2030. Optical imaging systems offer great potential for diagnosis, improving disease prevention and treatment in the healthcare sector. Digital Patient Monitoring Devices Market Segmentation Grand View Research has segmented the global digital patient monitoring devices market on the basis of type, product, and region: Digital Patient Monitoring Devices Type Outlook (Revenue, USD Million, 2016 - 2028) • Wireless Sensor Technology • mHealth • Telehealth • Wearable Devices • Remote Patient Monitoring Digital Patient Monitoring Devices Product Outlook (Revenue, USD Million, 2016 - 2028) • Diagnostic Monitoring Devices • Therapeutic Monitoring Devices Digital Patient Monitoring Devices Regional Outlook (Revenue, USD Million, 2016 - 2028) • North America • Europe • Asia Pacific • Latin America • Middle East & Africa (MEA) Key Companies profiled: Some prominent players in the Global Digital Patient Monitoring Devices Market include • GE Healthcare • AT&T • ATHENAHEALTH, INC. • Abbott • Koninklijke Philips N.V. AB • Hill-Rom Services Inc. • Medtronic • Omron Healthcare, Inc. • FitBit, Inc. • Garmin Ltd. • VitalConnect • ResMed • Siren Order a free sample PDF of the Digital Patient Monitoring Devices Market Intelligence Study, published by Grand View Research. Drug Discovery Informatics Industry Overview
The global drug discovery informatics market size was valued at USD 2.39 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 11.3% from 2021 to 2028. The drug discovery informatics market is set to gain momentum in the coming years due to advancements in high-performance computing & web services, increasing adoption of in-silico modeling tools, the growing volume of drug discovery data, and rising demand for novel medicine moieties. The launch of advanced drug discovery information technology is set to intensify the industry competition. For instance, in January 2021, Certara, Inc. launched Simcyp Physiologically-based Pharmacokinetic (PBPK) Simulator platform version 20. The new models help in assessing and analyzing the drug action during pregnancy and lactation. Gather more insights about the market drivers, restrains and growth of the Global Drug Discovery Informatics Market In addition, it helps the customers with critical decisions regarding optimizing medicine safety and efficacy profile. Companies are also increasingly adopting informatics solutions to shorten the long drug discovery timeline. For instance, in December 2020, Curve Therapeutics Ltd. implemented the CDD Vault platform for managing its genetically encoded Microcycle platform. It is a ubiquitous hosted platform suitable for applications across pharmaceutical, biotechnology, and academic institutes for securing and seamless sharing of data in real-time, thereby facilitating collaborative discoveries. Moreover, the accelerated Covid-19 drug discovery around the world is further contributing to the market growth. For instance, for providing fast-track solutions, scientists performed virtual screening using medicine from the DrugBank, for targeting the viral proteins and human ACE2 receptors. These studies were based on in silico tools for screening small molecules that have the potential usage in drug discoveries against Covid-19. Similarly, companies are developing several web services & solutions for supporting various steps of drug development for Covid-19. For instance, in June 2020, the IBM visual molecular explorer platform explored a selected set of the generated molecules targeting the coronavirus (SARS-CoV-2). The open-source sharing of the AI-generated artefacts in the explorer helped in the initial stages of optimal medicine designing. Browse through Grand View Research's Pharmaceuticals Industry Research Reports. • Peptide Antibiotics Market: The global peptide antibiotics market size was valued at USD 4.37 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 4.6% from 2022 to 2030. The factors responsible for driving the growth of the market are increasing demand of peptide antibiotics in hospitals and clinics, increasing prevalence of diseases such as, bacterial skin infections, blood stream infections, and hospital acquired infections. • Specialty Generics Market: The global specialty generics market size was valued at USD 67.2 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 9.2% from 2022 to 2030. The increasing adoption of specialty generic medicines for the treatment of complex chronic diseases such as hepatitis C and their increasing prevalence is a key driver for the market. Drug Discovery Informatics Market Segmentation Grand View Research has segmented the global drug discovery informatics market on the basis of workflow, mode, services, and region: Drug Discovery Informatics Workflow Outlook (Revenue, USD Million, 2017 - 2028) • Discovery Informatics • Development Informatics Drug Discovery Informatics Mode Outlook (Revenue, USD Million, 2017 - 2028) • Outsourced • In-house Drug Discovery Informatics Services Outlook (Revenue, USD Million, 2017 - 2028) • Sequence Analysis Platforms • Molecular Modeling • Docking • Clinical Trial Data Management • Others Services Drug Discovery Informatics Regional Outlook (Revenue, USD Million, 2017 - 2028) • North America • Europe • Asia Pacific • Latin America • Middle East & Africa Key Companies profiled: Some prominent players in the Global Drug Discovery Informatics Market include • Certara • Boehringer Ingelheim International GmbH • Infosys Ltd. • Charles River Laboratories • Eurofins DiscoverX Products • Jubilant Biosys • Selvita • Novo Informatics Pvt. Ltd. • ChemAxon Ltd. • Albany Molecular Research Inc. • Oracle • Accenture • Agilent Technologies, Inc. • Illumina, Inc. Order a free sample PDF of the Drug Discovery Informatics Market Intelligence Study, published by Grand View Research. Orthopedic Navigation Systems Industry Overview
The global orthopedic navigation systems market size was valued at USD 1.97 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 14.4% over the forecast period. Rising geriatric population & cases of joint reconstruction, growing healthcare expenditure, and high awareness levels among patients & healthcare professionals are expected to drive the market growth over the forecast years. There is an increase in the number of cases of orthopedic conditions, including osteoporosis, osteoarthritis, rheumatoid arthritis, and ligamentous knee injuries. These ailments affect the body's musculoskeletal system, which comprises muscles, bones, joints, nerves, ligaments, cartilage, and tendons. This results in a reduction in the range of motion, stiffness, swelling, and muscle pain that later requires surgical treatment. Gather more insights about the market drivers, restrains and growth of the Global Orthopedic Navigation Systems Market This is anticipated to boost the demand for the orthopedic navigation system in the coming years. According to the CDC estimation, 54.4 million (or 1 in 4) U.S. adults have some form of arthritis, which is expected to reach 78 million by the year 2040. This indicates the potential need for navigation systems for orthopedic surgeries in foreseeable future. Facing the outbreak of COVID-19, many countries made the required decision to abandon all non-emergency surgical procedures to free up caregivers for patients with COVID-19. The pandemic has adversely affected the overall market owing to restrictions on non-emergency procedures, which resulted in delays to several procedures consequently causing massive revenue losses for the orthopedic companies. For instance, Stryker’s net revenue decreased by 9.1% from last year and Smith & Nephew’s revenue decreased by 11.2% in 2020 from 2019. However, from the 3rd quarter, the market started recovering and began working rapidly as hospitals have gradually started resuming elective procedures. Therefore, in the coming years, it is projected that the market for orthopedic navigation systems will recover rapidly after the resumption of surgical procedures at full force. Associated advantages of Computer-assisted Surgeries (CAS), such as low blood loss, shorter hospital stays, and easier rehabilitation, are other factors expected to drive the industry revenue. CAS is instrumental in delivering accurate implant alignment, provides improved functionality, improves quality-adjusted life year, and causes less pain & tissue damage and fewer complications. Due to the abovementioned factors, demand for minimally invasive surgery is increasing rapidly. Furthermore, technological advancement in orthopedic surgical navigation procedures, increasing incidence of osteoarthritis, and rise in funding pertaining to R&D are other factors expected to boost the demand. Browse through Grand View Research's Medical Devices Industry Research Reports. • Urethral Dilators Market: The global urethral dilators market size was valued at USD 218.71 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 5.7% from 2022 to 2030. The demand for urethral dilators is increasing owing to the high prevalence of chronic kidney diseases, rise in the cases of urinary stones and urinary tract infections, and the rapidly growing baby boomer population. • Kidney Stone Retrieval Devices Market: The global kidney stone retrieval devices market size was valued at USD 2.66 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 3.7% from 2022 to 2030. The increasing number of technological advancements and the emergence of new procedures are some of the factors that are expected to drive the market for kidney stone retrieval devices during the next few years. Orthopedic Navigation Systems Market Segmentation Grand View Research has segmented the global orthopedic navigation systems market on the basis of application, technology, end-use, and region: Orthopedic Navigation Systems Application Outlook (Revenue, USD Million, 2016 - 2028) • Knee • Hip • Spine Orthopedic Navigation Systems Technology Outlook (Revenue, USD Million, 2016 - 2028) • Electromagnetic • Optical • Others Orthopedic Navigation Systems End-use Outlook (Revenue, USD Million, 2016 - 2028) • Hospitals • Ambulatory Surgical Centers (ASCs) Orthopedic Navigation Systems Regional Outlook (Revenue, USD Million, 2016 - 2028) • North America • Europe • Asia Pacific • Latin America • Middle East and Africa Key Companies profiled: Some prominent players in the Global Orthopedic Navigation Systems Market include • B. Braun Melsungen AG • Stryker • Medtronic • Smith+Nephew • Johnson & Johnson Services, Inc. (DePuy Synthes) • Zimmer Biomet • Amplitude Surgical • Kinamed, Inc. • Globus Medical • OrthAlign Order a free sample PDF of the Orthopedic Navigation Systems Market Intelligence Study, published by Grand View Research. Scanning Electron Microscopes Industry Overview
The global scanning electron microscopes market size was valued at USD 3.4 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 8.52% from 2021 to 2028. Key drivers of the market include increasing demand for nanotechnology-based research and consequent rise in funding. Furthermore, growing product application in the semiconductor, electronics, and pharmaceutical industries is expected to drive the market over the forecast period. In addition, improvements in the resolution power and features like attachment of other devices, such as energy x-ray dispersion spectrometer, are expected to propel market growth over the forecast period. A key reason for the success of Scanning Electron Microscopes (SEMs) is that they are widely used by small- to medium-scale R&D institutes and pharmaceutical companies. They provide researchers and quality assurance personnel with data regarding surface morphology and properties, such as topography, chemical analysis, fractography, etc. For example, the Zeiss Gemini 500 is a high-resolution Field Emission Scanning Electron Microscope (FE-SEM) that delivers nanoscale imaging from 100 mm diameter wafers down to small pieces. It has excellent resolution and image quality at high and low accelerating voltages. Gather more insights about the market drivers, restrains and growth of the Global Scanning Electron Microscopes Market As nanotechnology has applications in most of the areas of semiconductors, material sciences, and life sciences, which substantially affect the economy of any nation, it promotes government organizations and other corporate enterprises to support the R&D via public funding. The global market is observing higher growth owing to various driving factors, such as it is one of the most vital devices to analyse nanomaterials at the atomic scale in many pharmaceutical industries, medical devices, and numerous industry verticals. Semiconductor device manufacturing requires microscopes for procedures, such as lithography, coating, failure analysis, and detection. Growth of the semiconductor industry at a rapid pace in nations, such as India and China, owing to the outsourcing of electric equipment manufacturing is a major driver of the SEMs market. Increasing global focus on R&D for applications, such as neurosciences, material sciences, life sciences, nanotechnology, and semiconductor industry, would increase the adoption rate for advanced and automated microscopes, such as scanning probe microscope, analytical electron microscope, and SEMs. These microscopes provide imaging resolution as high as 0.1 nm, which is necessarily required for these precision manufacturing industries. These applications are sub-segments of the semiconductor industry, which are recently gaining enormous demand in the market. According to Moore’s law, the semiconductor industry is constantly moving towards the miniaturization of transistor chips. These trends of miniaturization of transistor chips requiring advanced microscopes, such as TEM, SEM, and SPM, for analytical and quality assurance purposes will provide great market potential over the next seven years. Browse through Grand View Research's Medical Devices Industry Research Reports. • Audiology Devices Market: The global audiology devices market size was valued at USD 8.9 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 7.1% from 2022 to 2030. The industry growth can be attributed to factors, such as the growing geriatric population and cases of hearing disorders along with supportive government initiatives for easy access to hearing aid. • Corneal Implants Market: The global corneal implants market size was valued at USD 392.9 million in 2021 and is anticipated to register a compound annual growth rate (CAGR) of 6.5% from 2022 to 2030. The increasing prevalence of ophthalmic diseases, such as keratoconus, Fuchs dystrophy, and infectious keratitis, is the key factor propelling the industry's growth. Scanning Electron Microscopes Market Segmentation Grand View Research has segmented the global scanning electron microscopes market on the basis of application and region: Scanning Electron Microscope Application Outlook (Revenue, USD Million, 2016 - 2028) • Material Science • Nanotechnology • Life Science • Semiconductors • Other Applications Scanning Electron Microscope Regional Outlook (Revenue, USD Million, 2016 - 2028) • North America • Europe • Asia Pacific • Latin America • Middle East & Africa (MEA) Key Companies profiled: Some prominent players in the Global Scanning Electron Microscopes Market include • Bruker Corp. • Danish Micro Engineering (DME) • Thermo Fisher Scientific • Hitachi High Technologies Corp. • JEOL Ltd. • Leica Microsystems • Nanoscience Instruments, Inc. • Nikon Corp. • Olympus Corp. • Carl Zeiss Order a free sample PDF of the Scanning Electron Microscopes Market Intelligence Study, published by Grand View Research. Kidney Function Tests Industry Overview
The global kidney function tests market size was valued at USD 777.06 million in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 6.2% from 2021 to 2028. Factors, such as investments by market players, increasing R&D activities, high prevalence of kidney diseases, and rising government initiatives, are expected to significantly drive market growth. Kidney function tests are simple laboratory tests used for investigating and evaluating functions of the kidney. Increased risk of Chronic Kidney Disease (CKD) and Acute Kidney Injury (AKI) due to the rising prevalence of diabetes and hypertension has drastically upsurged the demand for these products. The outbreak of coronavirus has further fueled the product demand. According to the study published by the National Kidney Foundation, people hospitalized due to Covid-19 are at significant risk of developing AKI. The study stated that Covid-19 patients were twice as likely to develop AKI as compared to non-Covid-19 patients. Health authorities recommended that Covid-19 patients who had an AKI should be tested regularly as their risk of developing CKD is higher than others. These factors will propel the kidney function tests market growth over the forecast period. Gather more insights about the market drivers, restrains and growth of the Global Kidney Function Tests Market Rising R&D initiatives for the development of novel products are expected to significantly boost market growth during the forecast period. For instance, in January 2020, Germany-based SphingoTec GmbH launched its IB10 sphingotest penKid, a Point-of-Care (PoC) test for Proenkephalin (penKid). This biomarker enables real-time evaluation of kidney function with a normal blood test. In addition, growing investments in the field of kidney function testing are further expected to fuel the market growth. In January 2020, Sweden-based Elypta AB raised a seed round worth USD 7.0 million to develop the first urine test for kidney cancer. Chronic kidney disease has become a global public health problem having a high economic cost associated with it. According to the National Institutes of Health (NIH), the global prevalence of CKD is around 14.0%. Also, the prevalence of CKD risk factors, such as diabetes, hypertension, and obesity, is on the rise owing to lifestyle changes. This has led to an increased demand for mandatory screening tests in patients with hypertension and diabetes for CKD, thus creating a high product demand. As per the data published by the International Diabetes Federation, in 2019, around 463.0 million adults had diabetes globally, which is predicted to reach 700 million by 2045. Furthermore, several public-private organizations are undertaking initiatives to facilitate kidney disease testing in key regions. For instance, in July 2020, the National Kidney Foundation (NKF) in collaboration with the National Committee for Quality Assurance (NCQA), introduced a new kidney health evaluation measure, specifically for patients with diabetes. The new guidelines suggest routinely test of diabetes patients for kidney diseases. Such initiatives are anticipated to create a lucrative environment for market growth. Browse through Grand View Research's Clinical Diagnostics Industry Research Reports. • Molecular Diagnostics Market: The global molecular diagnostics market size was valued at USD 37.04 billion in 2021 and is expected to decline at a compound annual growth rate (CAGR) of -1.6% from 2022 to 2030. The shrinking of the market can be attributed to the decline in demand for molecular COVID-19 testing during the forecast period. • In Vitro Diagnostics Market: The global in vitro diagnostic market size was valued at USD 111.67 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 0.2% from 2022 to 2030. The growth can be attributed to the increasing adoption of IVDowing to the rise in testing due to the pandemic. Kidney Function Tests Market Segmentation Grand View Research has segmented the global kidney function tests market on the basis of product, end-use, and region: Kidney Function Tests Product Outlook (Revenue, USD Million, 2016 - 2028) • Clearance Tests • Urine Tests • Blood Tests • Dilution and Concentration Tests • Other Tests Kidney Function Tests End-use Outlook (Revenue, USD Million, 2016 - 2028) • Hospitals • Diagnostic Laboratories • Research Laboratories and Institutes • Others Kidney Function Tests Regional Outlook (Revenue, USD Million, 2016 - 2028) • North America • Europe • Latin America • Asia Pacific • MEA Key Companies profiled: Some prominent players in the Global Kidney Function Tests Market include • Abbott Laboratories • Danaher Corporation (Beckman Coulter, Inc.) • F. Hoffmann-La Roche • Sysmex Corporation • Siemens Healthineers • Randox Laboratories • Quest Diagnostics • Acon Laboratories • Nova Biomedical • Laboratory Corporation of America Holdings (LabCorp) Order a free sample PDF of the Kidney Function Tests Market Intelligence Study, published by Grand View Research. ENT Devices Market Latest Trends, Drivers, Growth And Analysis Report with Major Players by 20289/15/2022 ENT Devices Industry Overview
The global ENT devices market size was valued at USD 20.7 billion in 2020 and is estimated to expand at a compound annual growth (CAGR) of 4.7% from 2021 to 2028. The rising geriatric population, increasing prevalence of ENT-related disorders, increasing penetration of minimally invasive ENT procedures are among the key trends stimulating market growth. Technological advancements also play an important role in the growth of the market. Demand for advanced ENT devices and systems, such as robot-assisted endoscopes, in developing economies is low due to high cost, as their use is concentrated to developed economies, such as the U.S. However, increasing healthcare spending by other governments and a rise in per capita income are anticipated to significantly improve market penetration. Sales are expected to increase at a rapid pace in developing economies due to the high incidence of ENT diseases, such as hearing loss and sinusitis, and an increase in efforts to provide better access to healthcare facilities in these regions. Gather more insights about the market drivers, restrains and growth of the Global ENT Devices Market Hearing loss/impairment has become one of the most common conditions in patients, especially in industrialized countries. According to the WHO, there are over 460 million people worldwide, i.e., around 5% of the world’s population, living with disabling hearing loss, which is expected to increase to over 900 million or 1 in every 10 people by 2050. Two of the main reasons for this are growing life expectancy and increasing noise pollution, which means more cases of age-related hearing loss. Infections such as measles, middle ear infection, or meningitis are also common causes of hearing loss in low-income countries. Moreover, chronic inflammation, noise exposure, vascular disorders, physiological aging of the ear, and genetic susceptibility may cause hearing impairment. ENT devices for minimally invasive procedures are dominated by companies such as Karl Storz, which offers HD video rhino-laryngoscope that can be used for visualization of nose, pharynx, & larynx in HD image quality. Ambu, Inc. also offers single-use rhino-laryngoscope, which provides ENT specialists an alternative to reusable scopes. In March 2019, the company received CE Mark for Ambu aScope 4 RhinoLaryngo Slim. Browse through Grand View Research's Medical Devices Industry Research Reports. • Mammography Market: The global mammography market size was valued at USD 1.95 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 10.26% from 2022 to 2030. The rising prevalence of breast cancer and increasing demand for early-stage diagnosis among patients are some of the key factors anticipated to drive demand for breast cancer diagnostic devices over the forecast period. • Health Sensors Market: The global health sensors market size was valued at USD 41.18 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 18.53% from 2022 to 2030. The growth is attributed to technological advancements, rising demand for round-the-clock monitoring, increasing demand for health data tracking, and rising incidence of chronic diseases. ENT Devices Market Segmentation Grand View Research has segmented the global ENT devices market on the basis of product and region: ENT Devices Product Outlook(Revenue, USD Million, 2016 - 2028) • Diagnostic ENT Devices • Surgical ENT Devices • Hearing Aids • Hearing Implants • Nasal Splints ENT Devices Regional Outlook(Revenue, USD Million, 2016 - 2028) • North America • Europe • Asia Pacific • Latin America • Middle East & Africa (MEA) Key Companies profiled: Some prominent players in the Global ENT Devices Market include • Demant A/S • Sonova • Ambu A/S • Pentax Medical • Karl Storz • Olympus Corporation • Richard Wolf Gmbh • Widex • Cochlear Ltd. • Sivantos, Inc. • Starkey Hearing Technologies • GN Resound A/S • Rion Co., Ltd. • Welch Allyn • Atos Medical AB Order a free sample PDF of the ENT Devices Market Intelligence Study, published by Grand View Research. Continuous Glucose Monitoring Device Industry Overview
The global continuous glucose monitoring device market size was valued at USD 4.7 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 10.1% from 2021 to 2028. Key factors driving this market are the rising incidence of diabetes, coupled with the increasing geriatric population prone to diabetes. The Continuous Glucose Monitoring (CGM) devices market is further propelled by growing awareness about diabetes preventive care, new product launches, and supportive government initiatives. Increased demand for continuous glucose monitoring devices amid the COVID-19 pandemic is attributed to the loosened restricted regulations and issued guidelines for the use of home-use glucose meters or CGMs in hospital settings by the federal agencies. The CGMs approved for hospital use include the Dexcom G6 and Abbott FreeStyle Libre. Gather more insights about the market drivers, restrains and growth of the Global Continuous Glucose Monitoring Device Market This was mainly done to ensure the safety of healthcare workers and self-testing among the patients. The American Diabetic Association also issued several resources on COVID-19 and diabetes. Delayed diagnosis due to lockdown restrictions and low awareness among several developing countries are likely to hamper the adoption of these devices. According to the survey conducted by Novartis AG, only 7% of individuals visit doctors at an early or pre-diabetic stage, leaving a staggering 93% with already developed type 2 diabetes. A rise in the incidence of diabetes due to aging, obesity, and an unhealthy lifestyle is one of the factors contributing to the growth of the market. Obesity is a major factor leading to diabetes. According to WHO, in 2016, over 1.9 billion adults were overweight, of which, around 650 million people were obese. These devices allow the observation of blood glucose at various time intervals with the help of a sensor and these readings are transmitted over a wireless network. Respective readings are fed into diabetes management software to allow the patient to understand the disease better, in turn, helping them to manage it better. Browse through Grand View Research's Medical Devices Industry Research Reports. • Corneal Implants Market: The global corneal implants market size was valued at USD 392.9 million in 2021 and is anticipated to register a compound annual growth rate (CAGR) of 6.5% from 2022 to 2030. The increasing prevalence of ophthalmic diseases, such as keratoconus, Fuchs dystrophy, and infectious keratitis, is the key factor propelling the industry's growth. • Hyperspectral Imaging Systems Market: The global hyperspectral imaging systems market size was valued at USD 10.36 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 10.1% from 2022 to 2030. Increasing application of hyperspectral imaging in various sectors, such as R&D, healthcare, defense, food industry, night vision, and remote sensing is anticipated to create high demand in the market. Continuous Glucose Monitoring Device Market Segmentation Grand View Research has segmented the global continuous glucose monitoring device market on the basis of component, end use, and region: CGM Devices Component Outlook (Revenue, USD Million, 2016 - 2028) • Transmitters • Sensors • Receivers CGM Devices End-use Outlook (Revenue, USD Million, 2016 - 2028) • Hospitals • Home Care • Others CGM Devices Regional Outlook (Revenue, USD Million, 2016 - 2028) • North America • Europe • Asia Pacific • Latin America • MEA Key Companies profiled: Some prominent players in the Global Continuous Glucose Monitoring Device Market include • Medtronic • Dexcom, Inc. • F. Hoffmann-La Roche Ltd. • Abbott • Novo Nordisk A/S • Ypsomed • GlySens, Inc. Order a free sample PDF of the Continuous Glucose Monitoring Device Market Intelligence Study, published by Grand View Research. Intravenous Iron Drugs Industry Overview
The global intravenous iron drugs market size was valued at USD 2.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 8.5% from 2021 to 2028. The growing prevalence of Chronic Kidney Disease (CKD), Inflammatory Bowel Disease (IBD), and cancer around the globe has led to an increase in the need for intravenous iron drugs for the treatment of subsequent Iron Deficiency Anemia (IDA), which is expected to propel market growth. Furthermore, approval and launch of novel formulations and strategic initiatives undertaken by key players to improve access to intravenous iron drugs are further expected to support market growth. The COVID-19 outbreak has disrupted manufacturing and supply of intravenous iron drugs, however, robust initiatives by manufacturer and government to meet the demand has supported the growth of the market for intravenous iron drugs. In addition, various studies have suggested that Covid-19 infection has increased risk of Acute Kidney Injury (AKI) and CKD, which, in turn, has fueled the demand for intravenous iron drugs for the treatment of CKD-related anemia. According to the study published by the National Kidney Foundation, people hospitalized with COVID-19 are at significant risk of AKI. The study stated that patients hospitalized with COVID-19 were twice as likely to develop AKI as compared to non-COVID patients. Health authorities recommended that COVID-19 patients who had an AKI should be tested regularly as their risk of developing CKD is higher than others. Gather more insights about the market drivers, restrains and growth of the Global Intravenous Iron Drugs Market Anemia is one of the most common blood disorders in recent times. According to the National Heart, Lung, and Blood Institute, an estimated 3 million individuals suffer from anemia in the U.S. Increasing prevalence of target diseases, such as rheumatoid arthritis, autoimmune diseases, kidney conditions, cancer, liver disorders, thyroid diseases, and inflammatory bowel diseases, is a major factor facilitating the growth of the market for intravenous iron drugs. Some of the most common forms of anemia are iron and vitamin deficiency, a plastic, hemolytic, and sickle cell. Some of the common causes of anemia are iron, vitamin A and B12, and folate deficiencies. Infectious diseases such as tuberculosis, parasitic infections, malaria, and HIV are major causes of anemia across the globe. Data from WHO indicates that approximately 42% of children below the age of 5 and 40% of pregnant women are suffering from some form of anemia. According to the National Kidney Foundation, Inc., the two major causes of CKD are diabetes and hypertension. Data from the same source also indicates an estimated 10% of the global population is affected by chronic kidney disease, with over 2 million individuals receiving dialysis on a regular basis. The majority of these individuals are typically seen across countries such as Italy, the U.S., Germany, Japan, and Brazil. A vast majority of individuals suffering from the disease are not aware until serious symptoms manifest. It is estimated that the incidence of chronic kidney cases will rise across developing economies, such as India and China, which implies an increase in the geriatric population over the coming years. With the growing prevalence of these diseases, the need for intravenous iron drugs has risen significantly. One of the major drawbacks of oral iron drugs is their risk of severe adverse effects. Common adverse effects of oral iron drugs include digestive problems such as stomach aches, constipation, loss of appetite, nausea, and vomiting. The overdose of oral iron drugs may also induce convulsions, shallow or rapid breathing, tiredness or weakness, fatigue, pale skin, and bluish skin or fingernails. The use of intravenous iron drugs, on the other hand, has shown to bring about increased iron uptake by the body, facilitating Erythropoiesis-stimulating Agents (ESAs) to function in an enhanced manner to lower anemic conditions. Other advantages of intravenous iron drugs include the preservation of heart health and the ability to be used by dialysis patients, especially those undergoing hemodialysis. These adverse effects are, hence, anticipated to facilitate the switch to intravenous iron drugs, increasing the uptake of the same during the forecast period. Browse through Grand View Research's Pharmaceuticals Industry Research Reports. • Alopecia Market: The global alopecia market size was valued at USD 7.6 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 8.1% from 2021 to 2028. The increasing prevalence of hair loss, technological advancements in alopecia treatment, and the rise in prevalence of chronic diseases that are associated with hair loss are some of the major factors driving the market. • Pharmaceutical Manufacturing Market: The global pharmaceutical manufacturing market size was valued at USD 405.52 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 11.34% from 2021 to 2028. The pharmaceutical landscape has undergone a massive transformation with the emergence of new technologies, cost-effective, and more efficient manufacturing approaches. Intravenous Iron Drugs Market Segmentation Grand View Research has segmented the global intravenous iron drugs market on the basis of product, application, and region: Intravenous Iron Drugs Product Outlook (Revenue, USD Million, 2016 - 2028) • Iron Dextran • Iron Sucrose • Ferric Carboxymaltose • Others Intravenous Iron Drugs Application Outlook (Revenue, USD Million, 2016 - 2028) • Chronic Kidney Disease • Inflammatory Bowel Disease • Cancer • Others Intravenous Iron Drugs Regional Outlook (Revenue, USD Million, 2016 - 2028) • North America • Europe • Asia Pacific • Latin America • MEA Key Companies profiled: Some prominent players in the Global Intravenous Iron Drugs Market include • Vifor Pharma Management Ltd. • AMAG Pharmaceuticals • Daiichi Sankyo Company, Ltd. (American Regent. Inc.) • Sanofi S.A. • Pharmacosmos A/S • Shield Therapeutics Plc • AbbVie Inc. (Allergan Plc) Order a free sample PDF of the Intravenous Iron Drugs Market Intelligence Study, published by Grand View Research. Fundus Cameras Market Latest Trends, Drivers, Growth And Analysis Report with Major Players to 20289/14/2022 Fundus Cameras Industry Overview
The global fundus cameras market size was valued at USD 303.2 million in 2020 and is expected to expand at a CAGR of 5.8% from 2021 to 2028. The increasing geriatric population and chronic disorders, such as diabetes and hypertension, are responsible for the growth in the incidence of retinal disorders. Key retinal disorders include Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), and Retinopathy of Prematurity (ROP). Furthermore, increasing awareness about eye disorders and the commercialization of several technologically advanced products are likely to propel the market during the forecast period. Gather more insights about the market drivers, restrains and growth of the Global Fundus Cameras Market Diabetic eye diseases consist of a group of several eye conditions that include DR, diabetic macular edema, glaucoma, and cataract. According to the National Eye Institute (NEI), the U.S., the diabetic retinopathy patients in America are expected to double from 7.7 million in 2010 to 14.6 million in 2050. In addition, advancements in the field are expected to drive the market during the forecast period. COVID-19 has negatively impacted the market as the data captured during the pandemic was not accurate and sufficient to determine the eye problem. Lack of data limited the tracing of disease, its management, and treatment. However, handheld fundus cameras can be a useful option in this pandemic, as their portability will help in capturing the retinal changes in COVID patients present in different settings or locations. Advancements from the digital camera, red-free fundus camera, film-based fundus camera to the development of other for clear and in-depth fundus imaging along with the growing adoption of these new technologies in emerging countries are anticipated to drive the market during the forecast period. Moreover, supportive government regulations are also expected to contribute to market growth. According to the laws and regulations of medical device agencies in the U.S. and Japan, the fundus imaging cameras must be replaced once in every 4 years. This law helps maintain the quality of instruments and, thereby, improves diagnosis and treatment. Hence, the law is likely to maintain the demand for devices in countries and boost the market. Browse through Grand View Research's Medical Devices Industry Research Reports. • Wearable Injectors Market: The global wearable injectors market size was valued at USD 6.66 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 15.29% from 2022 to 2030. The main market-driving factors are the prevalence of chronic illnesses, rising geriatric population, and growing concern over needle stick injuries. • Intrathecal Pumps Market: The global intrathecal pumps market size was valued at USD 325.6 million in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 5.2% from 2022 to 2030. The rising incidence of chronic disorders, such as cancer, back pain, and chronic pancreatitis, is the major factor anticipated to drive the industry's growth. Fundus Cameras Market Segmentation Grand View Research has segmented the global fundus cameras market based on product, end-use, and region: Fundus Cameras Product Outlook (Revenue, USD Million, 2016 - 2028) • Mydriatic Fundus Cameras • Non-Mydriatic Fundus Cameras • Hybrid Fundus Cameras • ROP Fundus Cameras Fundus Cameras End-use Outlook (Revenue, USD Million, 2016 - 2028) • Hospitals • Ophthalmology Clinics • Ophthalmic & Optometrist Offices Fundus Cameras Regional Outlook (Revenue, USD Million, 2016 - 2028) • North America • Europe • Asia Pacific • Latin America • Middle East & Africa Key Companies profiled: Some prominent players in the Global Fundus Cameras Market include • Carl Zeiss Meditec, Inc. • Kowa Company Ltd. • Optomed Oy (Ltd.) • Optovue, Incorporated • CenterVue SpA • NIDEK Co., Ltd. • Topcon Medical Systems, Inc. • Clarity Medical Systems, Inc. • Canon, Inc. Order a free sample PDF of the Fundus Cameras Market Intelligence Study, published by Grand View Research. |
Archives
September 2022
Categories |